Latigo Bio

Latigo Biotherapeutics, Inc. ("Latigo Bio") is a clinical-stage biotechnology company headquartered in Thousand Oaks, California, developing novel non-opioid medicines for acute and chronic pain. Its lead candidates LTG-001 and LTG-321 are oral NaV1.8 sodium-channel inhibitors targeting pain at its peripheral source without the addiction risk of opioids; LTG-001 holds FDA Fast Track designation and reported positive Phase 2b results in post-abdominoplasty acute pain, published in the New England Journal of Medicine in July 2026. The company was founded on human-genetics-validated targets and uses in-house AI/ML and structure-based drug design to optimize potency and selectivity. It debuted in 2024 with a $135M Series A and closed a $150M Series B in March 2025, backed by Westlake Village BioPartners, 5AM Ventures, Foresite Capital and Corner Ventures. Latigo is a therapeutics developer, not a software vendor: it publishes no public API, developer portal, SDK or machine-readable specification.

Latigo Bio is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Drug Discovery.

🌐 Visit website 📡 Source on GitHub

9.8/100 minimal ▬ flat Agent 3/100 human only Full breakdown ↓
scored 2026-08-25 · rubric v0.14.0

0 APIs

Company Biotechnology Pharmaceuticals Life Sciences Drug Discovery Clinical Trials Healthcare Pain Management Therapeutics

Kin Score

Kin Score How this is scored →
scored 2026-08-25 · rubric v0.14.0

Composite quality — 9.8/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Access Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Contract Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 3/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

Documented Reversibility 0 / 6

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 4 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Delegated User Identity 0 / 6

Protected Resource Metadata 0 / 5

Registration Without a Human 0 / 6

Agentic Commerce Surface 0 / 5

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/latigo-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 1

The organization behind the API

Website

Website

Source (apis.yml)

aid: latigo-bio
name: Latigo Bio
description: 'Latigo Biotherapeutics, Inc. ("Latigo Bio") is a clinical-stage biotechnology company headquartered in Thousand
  Oaks, California, developing novel non-opioid medicines for acute and chronic pain. Its lead candidates LTG-001 and LTG-321
  are oral NaV1.8 sodium-channel inhibitors targeting pain at its peripheral source without the addiction risk of opioids;
  LTG-001 holds FDA Fast Track designation and reported positive Phase 2b results in post-abdominoplasty acute pain, published
  in the New England Journal of Medicine in July 2026. The company was founded on human-genetics-validated targets and uses
  in-house AI/ML and structure-based drug design to optimize potency and selectivity. It debuted in 2024 with a $135M Series
  A and closed a $150M Series B in March 2025, backed by Westlake Village BioPartners, 5AM Ventures, Foresite Capital and
  Corner Ventures. Latigo is a therapeutics developer, not a software vendor: it publishes no public API, developer portal,
  SDK or machine-readable specification.'
url: https://raw.githubusercontent.com/api-evangelist/latigo-bio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-harvest-listing: https://forgeglobal.com/latigo-bio_stock/
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-23'
modified: '2026-08-23'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Drug Discovery
- Clinical Trials
- Healthcare
- Pain Management
- Therapeutics
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/latigo-bio-domain-security.yml
- type: Website
  url: https://latigobio.com/
- type: TermsOfService
  url: https://latigobio.com/terms-of-use/
- type: PrivacyPolicy
  url: https://latigobio.com/privacy-policy/
x-enrichment:
  date: '2026-08-23'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: 'Latigo Biotherapeutics is a clinical-stage drug developer whose product is a molecule (oral NaV1.8 inhibitors LTG-001/LTG-321),
    not software — it runs no developer program: api., developer., docs., dev., portal., app. and data.latigobio.com are all
    NXDOMAIN, github.com/latigobio and /LatigoBiotherapeutics 404, and the corporate site itself sits behind a SiteGround
    robot challenge that answers HTTP 202 with an identical challenge shell to every path, including all eight /.well-known/*
    probes.'
  evidence:
  - url: https://latigobio.com/openapi.json
    status: 202
  - url: https://latigobio.com/.well-known/agent-card.json
    status: 202
  - url: https://github.com/latigobio
    status: 404
  - url: https://registry.npmjs.org/latigobio
    status: 404
  checked: '2026-08-23'

Work with this as data

Every provider here is available over the APIs.io API and to AI agents over MCP.

MCP server

One button, every client — Claude, Cursor, VS Code and the rest.

https://apis.io/mcp

Tools for providers

9 MCP tools reach this

find_providersBrowse and filter every provider in the catalog.
get_provider_artifactsEvery artifact this provider publishes, grouped by type.
get_provider_operationsEvery operation across all of their OpenAPIs — one call instead of parsing every spec.
get_provider_toolsEvery MCP tool they ship, with the operation each wraps.
get_provider_evidenceHow each part of their score was established. Free — the basis for a claim should not sit behind it.
get_provider_ratingPRO — composite, band, trend and facet scores.
apis_io_searchSTART HERE — APIs, providers and tags for one query, each with its total.
resolveTurn a domain, URL or GitHub org into the provider it belongs to.
find_cohortsEvery scored population of providers in the catalog.

All 92 tools

Call it yourself

curl for this page

This provider

curl "https://apis.io/api/v1/providers/latigo-bio"

All providers

curl "https://apis.io/api/v1/providers?limit=25"

Every operation they expose

curl "https://apis.io/api/v1/providers/latigo-bio/operations?limit=25"

How their score was established

curl "https://apis.io/api/v1/providers/latigo-bio/evidence"

Discovery needs no key. Ratings and market analysis are Pro.

Get an API key

Free tier, no email required.

GitHub Google LinkedIn

A second provider on the same verified email joins the account you already have.